New Hampshire Trust Sells 645 Shares of CVS Health Co. (NYSE:CVS)

New Hampshire Trust reduced its position in shares of CVS Health Co. (NYSE:CVSFree Report) by 6.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,688 shares of the pharmacy operator’s stock after selling 645 shares during the quarter. New Hampshire Trust’s holdings in CVS Health were worth $686,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Weik Capital Management grew its stake in CVS Health by 0.7% in the 1st quarter. Weik Capital Management now owns 17,600 shares of the pharmacy operator’s stock valued at $1,781,000 after acquiring an additional 120 shares during the period. FCA Corp TX lifted its holdings in CVS Health by 0.6% in the 1st quarter. FCA Corp TX now owns 20,109 shares of the pharmacy operator’s stock valued at $2,035,000 after purchasing an additional 122 shares in the last quarter. Arvest Trust Co. N A lifted its holdings in CVS Health by 1.2% in the 4th quarter. Arvest Trust Co. N A now owns 11,157 shares of the pharmacy operator’s stock valued at $1,040,000 after purchasing an additional 131 shares in the last quarter. SOA Wealth Advisors LLC. lifted its holdings in CVS Health by 4.9% in the 4th quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock valued at $226,000 after purchasing an additional 133 shares in the last quarter. Finally, Apella Capital LLC lifted its holdings in CVS Health by 4.2% in the 4th quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock valued at $272,000 after purchasing an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 75.99% of the company’s stock.

CVS Health Stock Performance

Shares of CVS opened at $78.48 on Friday. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 0.77. CVS Health Co. has a 52-week low of $64.41 and a 52-week high of $83.25. The stock has a 50 day moving average price of $75.49 and a 200 day moving average price of $73.04. The company has a market capitalization of $98.76 billion, a price-to-earnings ratio of 12.15, a price-to-earnings-growth ratio of 1.03 and a beta of 0.51.

CVS Health (NYSE:CVSGet Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The company had revenue of $93.81 billion during the quarter, compared to analysts’ expectations of $90.58 billion. During the same quarter in the previous year, the business earned $1.99 earnings per share. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. Research analysts predict that CVS Health Co. will post 8.33 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date is Friday, April 19th. CVS Health’s dividend payout ratio is presently 41.18%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CVS. HSBC assumed coverage on CVS Health in a report on Friday, December 22nd. They issued a “buy” rating and a $94.00 price objective on the stock. Royal Bank of Canada reduced their price target on CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a report on Thursday, February 8th. Leerink Partnrs reiterated an “outperform” rating on shares of CVS Health in a report on Monday, February 26th. StockNews.com lowered shares of CVS Health from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Finally, Piper Sandler boosted their price objective on shares of CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $90.21.

Check Out Our Latest Report on CVS Health

Insider Buying and Selling

In related news, EVP Prem S. Shah sold 29,473 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the transaction, the executive vice president now owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.25% of the stock is currently owned by corporate insiders.

About CVS Health

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Further Reading

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.